Ira Greenspan Biography and Net Worth

Chairman of Scopus BioPharma


Ira Scott Greenspan is a Senior Advisor, director, and Chairman of our Executive Committee. Mr. Greenspan is Chairman and Chief Executive Officer of HCFP and Co-Chairman and Co-Managing Partner of HCFP/Capital Partners, and certain other affiliates of HCFP. Each of HCFP and Mr. Greenspan is a co-founder of Scopus. For more than 25 years, Mr. Greenspan has been a senior executive, partner and/or director of HCFP and its predecessors and related entities, including having served as Chairman and Co-Managing Partner of HCFP/Brenner Equity Partners, the indirect majority shareholder of HCFP/Brenner Securities LLC, a middle market investment bank originally founded by former senior executives and directors of Drexel Burnham Lambert. Mr. Greenspan has been chairman and/or a member of the board of directors of numerous public and private companies. For more than five years prior to entering the financial services industry, Mr. Greenspan was a corporate and securities lawyer at leading New York law firms, including as a Partner of the New York predecessor of Blank Rome. He began his law career at the New York predecessor of Sidley Austin.

Mr. Greenspan received his B.A., with high distinction, from Harpur College/Binghamton University, where he was elected to Phi Beta Kappa and Pi Sigma Alpha. Mr. Greenspan received his J.D. from New York University School of Law, where he was on the Editorial Board of the Annual Survey of American Law, an honorary law journal.

What is Ira Scott Greenspan's net worth?

The estimated net worth of Ira Scott Greenspan is at least $89.97 as of August 19th, 2021. Mr. Greenspan owns 81,790 shares of Scopus BioPharma stock worth more than $90 as of April 25th. This net worth approximation does not reflect any other assets that Mr. Greenspan may own. Additionally, Mr. Greenspan receives an annual salary of $200,000.00 as Chairman at Scopus BioPharma. Learn More about Ira Scott Greenspan's net worth.

How old is Ira Scott Greenspan?

Mr. Greenspan is currently 65 years old. There are 1 older executives and no younger executives at Scopus BioPharma. Learn More on Ira Scott Greenspan's age.

What is Ira Scott Greenspan's salary?

As the Chairman of Scopus BioPharma Inc., Mr. Greenspan earns $200,000.00 per year. Learn More on Ira Scott Greenspan's salary.

How do I contact Ira Scott Greenspan?

The corporate mailing address for Mr. Greenspan and other Scopus BioPharma executives is , , . Scopus BioPharma can also be reached via phone at 212-479-2513. Learn More on Ira Scott Greenspan's contact information.

Has Ira Scott Greenspan been buying or selling shares of Scopus BioPharma?

Ira Scott Greenspan has not been actively trading shares of Scopus BioPharma during the last quarter. Most recently, on Monday, August 23rd, Ira Scott Greenspan bought 500 shares of Scopus BioPharma stock. The stock was acquired at an average cost of $4.41 per share, with a total value of $2,205.00. Learn More on Ira Scott Greenspan's trading history.

Who are Scopus BioPharma's active insiders?

Scopus BioPharma's insider roster includes Ira Greenspan (Chairman), and Joshua Lamstein (Chairman). Learn More on Scopus BioPharma's active insiders.

Ira Scott Greenspan Insider Trading History at Scopus BioPharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2021Buy500$4.41$2,205.00View SEC Filing Icon  
8/19/2021Buy2,000$4.04$8,080.0081,790View SEC Filing Icon  
8/17/2021Buy1,000$4.13$4,130.00View SEC Filing Icon  
7/26/2021Buy400$4.76$1,904.00View SEC Filing Icon  
7/23/2021Buy1,100$4.77$5,247.00118,797View SEC Filing Icon  
2/24/2021Buy115$9.48$1,090.2080,790View SEC Filing Icon  
2/18/2021Buy2,200$10.04$22,088.0080,475View SEC Filing Icon  
2/16/2021Buy2,500$10.20$25,500.0080,475View SEC Filing Icon  
See Full Table

Ira Scott Greenspan Buying and Selling Activity at Scopus BioPharma

This chart shows Ira Scott Greenspan's buying and selling at Scopus BioPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scopus BioPharma Company Overview

Scopus BioPharma logo
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00
Low: $0.00
High: $0.11

Volume

950 shs

Average Volume

2,990 shs

Market Capitalization

$46,288.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01